Compare Stocks: KOD, CAPR, and IVVD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$9.07 -3.7%	$9.72	$2.96 ▼ $40.37	$526.74M	0.72	5.74 million shs	3.25 million shs
IVVD Invivyd	$0.76 +1.2%	$0.76	$0.53 ▼ $3.07	$222.63M	0.81	3.78 million shs	6.27 million shs
KOD Kodiak Sciences	$32.71 -0.4%	$39.25	$9.39 ▼ $47.84	$2.06B	2.18	644,759 shs	1.61 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	0.00%	+8.36%	+32.60%	-68.04%	+49.18%
IVVD Invivyd	0.00%	-3.84%	-20.56%	-22.13%	-34.32%
KOD Kodiak Sciences	0.00%	-0.55%	-17.90%	-9.49%	+255.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$9.07 -3.7%	$9.72	$2.96 ▼ $40.37	$526.74M	0.72	5.74 million shs	3.25 million shs
IVVD Invivyd	$0.76 +1.2%	$0.76	$0.53 ▼ $3.07	$222.63M	0.81	3.78 million shs	6.27 million shs
KOD Kodiak Sciences	$32.71 -0.4%	$39.25	$9.39 ▼ $47.84	$2.06B	2.18	644,759 shs	1.61 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	0.00%	+8.36%	+32.60%	-68.04%	+49.18%
IVVD Invivyd	0.00%	-3.84%	-20.56%	-22.13%	-34.32%
KOD Kodiak Sciences	0.00%	-0.55%	-17.90%	-9.49%	+255.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	2.33	Hold	$30.25	233.52% Upside
IVVD Invivyd	2.33	Hold	$8.00	959.18% Upside
KOD Kodiak Sciences	2.63	Moderate Buy	$48.14	47.18% Upside

Current Analyst Ratings Breakdown

Latest KOD, CAPR, and IVVD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/17/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$58.00
9/14/2026	CAPR Capricor Therapeutics	B Riley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00
9/14/2026	IVVD Invivyd	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/11/2026	CAPR Capricor Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/8/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/27/2026	IVVD Invivyd	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/25/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	$5.53 per share	N/A
IVVD Invivyd	$53.43M	4.17	N/A	N/A	$1.04 per share	0.73
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
IVVD Invivyd	-$52.49M	-$0.33	N/A	N/A	N/A	-183.90%	-59.73%	-48.97%	11/5/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)

Latest KOD, CAPR, and IVVD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/13/2026	Q2 2026	IVVD Invivyd	-$0.1067	-$0.14	-$0.0333	-$0.14	$14.40 million	$14.29 million
8/12/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	7.35	7.35
IVVD Invivyd	N/A	5.87	5.87
KOD Kodiak Sciences	N/A	2.49	2.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
IVVD Invivyd	70.36%
KOD Kodiak Sciences	89.06%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	9.20%
IVVD Invivyd	12.25%
KOD Kodiak Sciences	44.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	231	58.14 million	52.79 million	Optionable
IVVD Invivyd	122	294.76 million	258.65 million	Optionable
KOD Kodiak Sciences	124	62.85 million	34.94 million	Optionable

KOD, CAPR, and IVVD Headlines

Recent News About These Companies

HC Wainwright Reiterates "Buy" Rating for Kodiak Sciences (NASDAQ:KOD)

September 19 at 1:43 AM | americanbankingnews.com

Kodiak Sciences Inc. (NASDAQ:KOD) Given Average Recommendation of "Moderate Buy" by Brokerages

September 18 at 8:28 AM | marketbeat.com

Kodiak Sciences' (KOD) "Buy" Rating Reiterated at HC Wainwright

September 17 at 8:05 AM | marketbeat.com

Kodiak Sciences: Daybreak Needs To Deliver More Than A Passing Grade

September 16, 2026 | seekingalpha.com

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

...

September 13, 2026 | marketbeat.com

Squarepoint Ops LLC Boosts Position in Kodiak Sciences Inc. $KOD

September 12, 2026 | marketbeat.com

29,309 Shares in Kodiak Sciences Inc. $KOD Acquired by Legal & General Group Plc

September 8, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases Shares of 111,935 Kodiak Sciences Inc. $KOD

September 6, 2026 | marketbeat.com

Kodiak Sciences Inc. $KOD Shares Bought by Wellington Management Group LLP

September 5, 2026 | marketbeat.com

Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts

September 3, 2026 | insidermonkey.com

Kodiak Sciences Inc. $KOD is Braidwell LP's 9th Largest Position

September 3, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Buys Shares of 114,089 Kodiak Sciences Inc. $KOD

September 1, 2026 | marketbeat.com

4,135,355 Shares in Kodiak Sciences Inc. $KOD Bought by BlackRock Inc.

August 29, 2026 | marketbeat.com

Jupiter Topco LLC Purchases Shares of 1,526,006 Kodiak Sciences Inc. $KOD

August 28, 2026 | marketbeat.com

Deutsche Bank AG Invests $2.16 Million in Kodiak Sciences Inc. $KOD

August 28, 2026 | marketbeat.com

Boone Capital Management LLC Takes Position in Kodiak Sciences Inc. $KOD

August 27, 2026 | marketbeat.com

Algert Global LLC Purchases 38,546 Shares of Kodiak Sciences Inc. $KOD

August 27, 2026 | marketbeat.com

Kodiak Sciences Inc. (NASDAQ:KOD) Given Average Rating of "Moderate Buy" by Analysts

August 24, 2026 | marketbeat.com

ICONIQ Capital LLC Invests $49.34 Million in Kodiak Sciences Inc. $KOD

August 24, 2026 | marketbeat.com

Emerald Investment Advisers LLC Makes New Investment in Kodiak Sciences Inc. $KOD

August 23, 2026 | marketbeat.com

Bank of America Corp DE Boosts Stock Holdings in Kodiak Sciences Inc. $KOD

August 23, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KOD, CAPR, and IVVD Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$9.07 -0.35 (-3.72%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$9.16 +0.09 (+0.99%)

As of 09/18/2026 07:59 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Invivyd NASDAQ:IVVD

$0.76 +0.01 (+1.22%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.76 +0.01 (+0.75%)

As of 09/18/2026 07:58 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Kodiak Sciences NASDAQ:KOD

$32.71 -0.14 (-0.43%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$32.42 -0.30 (-0.90%)

As of 09/18/2026 07:30 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KOD, CAPR, and IVVD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KOD, CAPR, and IVVD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KOD, CAPR, and IVVD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KOD, CAPR, and IVVD Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

Invivyd NASDAQ:IVVD

Kodiak Sciences NASDAQ:KOD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KOD, CAPR, and IVVD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KOD, CAPR, and IVVD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KOD, CAPR, and IVVD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KOD, CAPR, and IVVD Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

Invivyd NASDAQ:IVVD

Kodiak Sciences NASDAQ:KOD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools